

Global Oncology Pharmaceuticals Market

https://marketpublishers.com/r/GE63C398CF7DEN.html

Date: September 2021

Pages: 143

Price: US\$ 2,750.00 (Single User License)

ID: GE63C398CF7DEN

Abstracts

REPORT SCOPE:

This report aims to provide a comprehensive study of the global market for oncology pharmaceuticals (cancer drugs). It provides a detailed description of the different oncology pharmaceutical types (targeted therapy, immunotherapy, chemotherapy and hormone therapy) and current and historical market revenues. The markets for oncology pharmaceuticals is also segmented based on indication (lung cancer, breast cancer, multiple myeloma, prostate cancer, non-Hodgkin's lymphoma, colorectal cancer and other cancers). The market revenue for each geographic segment, North America, Europe, Asia-Pacific and RoW, has also been provided in the report.

In order to provide in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also part of this report. This report includes oncology pharmaceutical pipeline analysis and detailed discussion of key marketed products. This report outlines driving and restraining factors of the oncology pharmaceuticals market.

REPORT INCLUDES:

74 tables

An overview of the global oncology pharmaceutical market

Estimation of the market size and analyses of global market trends, with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026

Highlights of the current and future market potential and quantification of



oncology pharmaceutical market based on region, drug type, and application

Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast

Detailed description of risk factors, pathogenesis and stages of cancer including the TNM staging system and number staging systems, and coverage of cancer metastases, treatment approaches and non-pharmaceutical approaches to cancer

Analysis of oncology pharmaceutical pipeline products with focus on promising pipeline molecules/ drugs in development, and coverage of technological advances, scientific discoveries, and new therapies

Detailed analysis of the regulatory framework and policies, and snapshot of FDA approved drugs for indications related to oncology

Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis

Comprehensive company profiles of the leading players of the industry including AbbVie, Amgen, AstraZeneca, Bayer, Eli Lilly, F. Hofmann-La Roche, Johnson & Johnson, Novartis, and Pfizer



Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Scope of Report
Methodology and Information Sources
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 BIOLOGY OF CANCER

Overview

Risk Factors for Cancer

Pathogenesis of Cancer

Stages of Cancer

The TNM Staging System

Number Staging Systems

Cancer Metastases

Routes of Metastasis

Drug Resistance

Inherent Resistance

Acquired Resistance

Treatment Approaches to Cancer

Non-pharmaceutical Approaches

Surgery for Cancer

Radiotherapy for Cancer

Ablation Therapy

Pharmacological Therapies

Personalized Cancer Therapy (Precision Medicine)

CHAPTER 4 MARKET BREAKDOWN BY DRUG TYPE

Overview

Chemotherapy



Types of Chemotherapy Pharmaceuticals

Hormone Therapy

Types of Hormone Therapy Pharmaceuticals

Targeted Therapy

Types of Targeted Therapy Pharmaceuticals

Small Molecule Targeted Agents

Monoclonal Antibodies (mAbs)

Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors

Targeted Radioligand Therapies

Immunotherapy

Types of Immunotherapy Pharmaceuticals

Immune Checkpoint Inhibitors

Immune-Modulating Small Molecule

Monoclonal Antibodies (mAbs)

Gene Therapies

Global Market for Oncology Pharmaceuticals by Drug Type

Global Market for Targeted Therapy Pharmaceuticals by Drug Type

Global Market for Immunotherapy Pharmaceuticals by Drug Type

Global Market for Chemotherapy Pharmaceuticals

Global Market for Hormone Therapy Pharmaceuticals

CHAPTER 5 MARKET BREAKDOWN BY APPLICATION

Overview

Lung Cancer

Diagnosis

Breast Cancer

Diagnosis

Multiple Myeloma

Diagnosis

Prostate Cancer

Diagnosis

Non-Hodgkin's Lymphoma

Diagnosis

Colorectal Cancer

Diagnosis

Other Cancers

Stomach Cancer

Liver Cancer



Cervical Cancer
Esophageal Cancer
Melanoma
Leukemia
Global Market for Oncology Pharmaceuticals by Cancer Type

CHAPTER 6 MARKET BREAKDOWN BY REGION

Global Markets for Oncology Pharmaceuticals by Region North America

North American Market for Oncology Pharmaceuticals by Type Europe

European Market for Oncology Pharmaceuticals by Type Asia-Pacific

Asia-Pacific Market for Oncology Pharmaceuticals by Type RoW

RoW Market for Oncology Pharmaceuticals by Type

CHAPTER 7 COMPETITIVE LANDSCAPE

Overview

Blockbuster Oncology Pharmaceutical Brands

Blockbuster Oncology Pharmaceuticals Brand Revenue

Blockbuster Oncology Pharmaceutical Brands, by Drug Type

Blockbuster Oncology Pharmaceuticals, by Company

Key Oncology Pharmaceutical Brands

Chemotherapy

Hormone Therapy

Targeted Therapy

Small Molecule Targeted Agents

mAb Targeted Therapy

PARP Inhibitors

Targeted Radioligand Therapies

Immunotherapy

Immune-Modulating Small Molecules

mAb Immune Therapy

Immune Checkpoint Inhibitors

Gene Therapies

Global Market Shares of Leading Companies



Recent Industry Activities

CHAPTER 8 NEW DEVELOPMENTS AND PIPELINE ANALYSIS

New Developments
Novel Oncology Drug Approvals
Biosimilar Approvals
Pipeline Analysis
Selected New Drug Molecules in Late Stages of Clinical Development
Most Studied Drug Molecules

CHAPTER 9 MARKET DYNAMICS

Overview

Market Trends and Growth Drivers

Favorable Global Demographics and Aging Population

Greater Incidence of Obesity and Diabetes

Robust Approval of Oncology Pharmaceuticals

Advances in Biochemistry and Genomics

High Unmet Need

Premium Pricing

Collaborations and Licensing Agreements

Mergers and Acquisitions

Challenges

Loss of Exclusivity and Genericization

Lack of Oncology Professionals

High Cost of Biologic Therapies

CHAPTER 10 IMPACT OF COVID-19 PANDEMIC

Implications on Cancer Diagnosis
Implications on Cancer Treatment
Impact on Oncology Pharmaceuticals Market

CHAPTER 11 COMPANY PROFILES

ABBVIE INC.

AMGEN INC.

ASTELLAS PHARMA INC.



ASTRAZENECA PLC
BAYER AG
BRISTOL-MYERS SQUIBB
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
MERCK & CO.
NOVARTIS AG
PFIZER INC.
SANOFI-AVENTIS
TAKEDA PHARMACEUTICAL CO. LTD.

CHAPTER 12 APPENDIX: ACRONYMS



List Of Tables

LIST OF TABLES

Summary Table: Global Market for Oncology Pharmaceuticals, by Type, Through 2026

Table 1: Current Cancer Treatment Options

Table 2: Types of Hormone Therapy Drugs

Table 3: Cancer Drug Treatment Classes

Table 4: Global Market for Oncology Pharmaceuticals, by Type, Through 2026

Table 5: Global Market for Targeted Therapy Pharmaceuticals, by Type, Through 2026

Table 6: Global Market for Immunotherapy Pharmaceuticals, by Type, Through 2026

Table 7: Global Market for Chemotherapy Pharmaceuticals, Through 2026

Table 8: Global Market for Hormone Therapy Pharmaceuticals, Through 2026

Table 9: Stages of Lung Cancer

Table 10: Estimated Numbers for All Cancers (Except Non-Melanoma Skin Cancer), 2020

Table 11: Global Market for Oncology Pharmaceuticals, by Cancer Type, Through 2026

Table 12: North American Market for Oncology Pharmaceuticals, by Type, Through 2026

Table 13: North American Market for Oncology Pharmaceuticals, by Type, Through 2026

Table 14: Demographic, Cancer and Healthcare Statistics for Selected European Countries

Table 15: Estimated Cancer Incidence and Mortality, Age Standardized Rate in EU Countries, by Cancer Type, 2020

Table 16: European Market for Oncology Pharmaceuticals, by Type, Through 2026

Table 17: Oncology Statistics, Asia-Pacific, 2020

Table 18: Notable Cancer Types, Asia-Pacific, 2020

Table 19: Asia-Pacific Market for Oncology Pharmaceuticals, by Type, Through 2026

Table 20: Cancer Statistics, South America and Africa, 2020

Table 21: RoW Market for Oncology Pharmaceuticals, by Type, Through 2026

Table 22: Blockbuster Oncology Pharmaceuticals, 2020

Table 23: Number of Blockbuster Oncology Pharmaceutical Brands, by Drug Type, 2020

Table 24: Selected Blockbuster Oncology Pharmaceuticals, by Company, 2020

Table 25: Key Chemotherapy Oncology Pharmaceuticals

Table 26: Key Hormone Therapy Oncology Pharmaceuticals

Table 27: Key Small Molecule Targeted Oncology Pharmaceuticals

Table 28: Key mAb Targeted Oncology Pharmaceuticals



- Table 29: Key PARP Inhibitors
- Table 30: Key Targeted Radioligands
- Table 31: Key Immune-Modulating Small Molecule Pharmaceuticals
- Table 32: Key mAb Immune Therapy Oncology Pharmaceuticals
- Table 33: Key Immune Checkpoint Inhibitor Oncology Pharmaceuticals
- Table 34: Key Genetically-Modified Autologous T-Cell Immunotherapy or CAR T-Cell
- Therapy Oncology Pharmaceuticals
- Table 35: Key Oncolytic Virus Therapy Oncology Pharmaceuticals
- Table 36: Leading Oncology Pharmaceuticals, 2020
- Table 37: Oncology Approvals
- Table 38: Novel Oncology Drug Approvals, Jan. 2019-July 2021
- Table 39: Biosimilar Approvals for Oncology Indications, 2018 and 2020
- Table 40: Selected New Oncology Drugs in Late Stages of Clinical Development
- Table 41: Selected Drug Molecules for Cancer Treatment, by Number of Clinical Trials
- Table 42: New Cancer Cases, U.S., 2018, by Age Group
- Table 43: Recent Deals and Acquisitions, Oncology Pharmaceutical Market, 2019-2021
- Table 44: AbbVie: Oncology Pharmaceuticals Product Portfolio
- Table 45: AbbVie: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 46: Amgen: Oncology Pharmaceuticals Product Portfolio
- Table 47: Amgen: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 48: Astellas: Oncology Pharmaceuticals Product Portfolio
- Table 49: Astellas: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 50: AstraZeneca: Oncology Pharmaceuticals Product Portfolio
- Table 51: AstraZeneca: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 52: Bayer: Oncology Pharmaceuticals Product Portfolio
- Table 53: Bayer: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 54: Bristol-Myers Squibb: Oncology Pharmaceuticals Product Portfolio
- Table 55: Bristol-Myers Squibb: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 56: Eli Lilly and Co.: Oncology Pharmaceuticals Product Portfolio
- Table 57: Eli Lilly and Co.: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 58: Roche: Oncology Pharmaceuticals Product Portfolio
- Table 59: Roche: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 60: Gilead Sciences Inc.: Oncology Pharmaceuticals Product Portfolio
- Table 61: Gilead Sciences Inc.: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 62: Johnson & Johnson: Oncology Pharmaceuticals Product Portfolio
- Table 63: Johnson & Johnson: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 64: Merck & Co.: Oncology Pharmaceuticals Product Portfolio
- Table 65: Merck & Co.: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 66: Novartis: Oncology Pharmaceuticals Product Portfolio



Table 67: Novartis: Oncology Pharmaceuticals Revenue, 2018-2020

Table 68: Pfizer: Oncology Pharmaceuticals Product Portfolio

Table 69: Pfizer: Oncology Pharmaceuticals Revenue, 2018-2020

Table 70: Sanofi-Aventis: Oncology Pharmaceuticals Product Portfolio

Table 71: Sanofi-Aventis: Oncology Pharmaceuticals Revenue, 2018-2020

Table 72: Takeda: Oncology Pharmaceuticals Product Portfolio

Table 73: Takeda: Oncology Pharmaceuticals Revenue, 2019-2021

Table 74: Acronyms Used in This Report



List Of Figures

LIST OF FIGURES

Summary Figure: Global Market for Oncology Pharmaceuticals, by Type, 2020-2026

Figure 1: Antibody Drug Conjugate

Figure 2: Benefits of Immunotherapy

Figure 3: Potential Targets for Checkpoint Inhibition in Clinical Evaluation

Figure 4: mAbs Mechanism of Action as Immunotherapy

Figure 5: Global Market Shares of Oncology Pharmaceuticals, by Type, 2020

Figure 6: Global Market Shares of Targeted Therapy Pharmaceuticals, by Type, 2020

Figure 7: Global Market Shares of Immunotherapy Pharmaceuticals, by Type, 2020

Figure 8: Five-Year Overall Survival Rates, U.S., by Cancer Type

Figure 9: Global Market Shares of Oncology Pharmaceuticals, by Cancer Type, 2020

Figure 10: Global Market Shares of Oncology Pharmaceuticals, by Region, 2020

Figure 11: North American Market Shares of Oncology Pharmaceuticals, by Type, 2020

Figure 12: European Market Shares of Oncology Pharmaceuticals, by Type, 2020

Figure 13: Asia-Pacific Market Shares of Oncology Pharmaceuticals, by Type, 2020

Figure 14: RoW Market Shares of Oncology Pharmaceuticals, by Type, 2020

Figure 15: Novel Oncology FDA Drug Approvals, 2016-2021

Figure 16: Clinical Trials, by Cancer Type

Figure 17: Rate of New Cancer Cases, U.S., 2018, by Age Group

Figure 18: Novel Oncology Drug FDA Approvals, 2016-2021

Figure 19: AbbVie's Hematologic Oncology Segment: Annual Revenue, 2018-2020

Figure 20: Amgen's Oncology Pharmaceuticals: Annual Revenue, 2018-2020

Figure 21: Astellas' Oncology Pharmaceuticals: Annual Revenue, 2018-2020

Figure 22: AstraZeneca's Oncology Segment: Annual Revenue, 2018-2020

Figure 23: Bayer's Oncology Pharmaceuticals: Annual Revenue, 2018-2020

Figure 24: Bristol-Myers Squibb Oncology Pharmaceutical: Annual Revenue, 2018-2020

Figure 25: Eli Lilly and Co.'s Oncology Segment: Annual Revenue, 2018-2020

Figure 26: Roche's Oncology Segment: Annual Revenue, 2018-2020

Figure 27: Gilead Sciences Inc.'s Oncology Pharmaceuticals: Annual Revenue, 2018-2020

Figure 28: Johnson & Johnson's Oncology Segment: Annual Revenue, 2018-2020

Figure 29: Merck & Co.'s Oncology Pharmaceuticals: Annual Revenue, 2018-2020

Figure 30: Novartis's Oncology Segment: Annual Revenue, 2018-2020

Figure 31: Pfizer's Oncology Segment: Annual Revenue, 2018-2020

Figure 32: Sanofi-Aventis' Oncology Pharmaceuticals: Annual Revenue, 2018-2020

Figure 33: Takeda's Oncology Pharmaceutical: Annual Revenue, 2018-2020



I would like to order

Product name: Global Oncology Pharmaceuticals Market

Product link: https://marketpublishers.com/r/GE63C398CF7DEN.html
Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

co. Cou zi, cono (emigro con ziconeo / ziconomo zonvery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GE63C398CF7DEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970